Literature DB >> 2023781

Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.

H Madersbacher1, G Jilg.   

Abstract

This report deals with the control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride (OH) in 10 male and 3 female patients with complete suprasacral spinal cord lesions having clean intermittent catheterisation (CIC) because of unbalanced voiding. The indication for intravesical OH application was persisting urinary incontinence despite CIC in 11 patients and in 2 patients detrusor hypercontractility. One 5 mg tablet of OH was dissolved in distilled water and the solution was instilled into the bladder through the catheter, which has been used for urodynamics and which was then removed. Six hours later cystometry was repeated and the clinical effects were studied especially with regard to continence/incontinence and side-effects. The differences in the cystometric bladder capacity and maximum detrusor pressure before and after instillation of OH are statistically highly significant. Clinically, from those 10 patients who were incontinent between CIC before, 9 remained dry during the 6-hour period. None of the patients reported any side-effect after intravesical application of OH. However, with subsequent oral medication 8 out of 12 patients complained of typical anticholinergic side-effects. These results indicate that treatment with topical OH is an effective alternative to treating detrusor hyperreflexia, especially in patients already on CIC because of unbalanced voiding, but with persisting urinary incontinence due to detrusor hyperreflexia. OH is well absorbed from the bladder, however absorption seems to be protracted compared to oral intake.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2023781     DOI: 10.1038/sc.1991.11

Source DB:  PubMed          Journal:  Paraplegia        ISSN: 0031-1758


  18 in total

1.  Transdermal systems for overactive bladder: principles and practice.

Authors:  David R Staskin
Journal:  Rev Urol       Date:  2003

2.  The management of urinary incontinence.

Authors:  P S Malone
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

3.  A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.

Authors:  Michael J Kennelly
Journal:  Rev Urol       Date:  2010

4.  Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.

Authors:  R H Zobrist; B Schmid; A Feick; D Quan; S W Sanders
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

5.  Intravesical oxybutynin affects bladder permeability.

Authors:  A Ersay; O C Demirtas
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

6.  Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.

Authors:  R Howard Zobrist; Danyi Quan; Heather M Thomas; Stephanie Stanworth; Steven W Sanders
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

7.  Vesical pacing in patients with overactive bladder: technique and results.

Authors:  Ahmed Shafik; Ismail Shafik; Olfat el-Sibai; Ali Shafik; Randa M Mostafa
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 8.  [Overactive bladder--treatment with antimuscarinic agents].

Authors:  K Höfner
Journal:  Urologe A       Date:  2003-05-20       Impact factor: 0.639

Review 9.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Authors:  Y E Yarker; K L Goa; A Fitton
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.